SD-101 With Immune Checkpoint Inhibition Generates Positive

Treatment with SD-101 distributed via pressure-enabled drug delivery with immune checkpoint inhibition was tolerated and resulted in the depletion of Tregs, M-MDSCs, and M2 macrophages in liver metastases in patients with uveal melanoma.

Related Keywords

San Diego , California , United States , Texas , Houston , Sapna Patel , Melanoma Fellowship Program , Department Of Melanoma Medical Oncology , University Of Texas Md Anderson Cancer Center , Uveal Melanoma Program , Melanoma Medical Oncology , Cancer Center , Esd 101 , M Mdscs , Pressure Enabled Drug Delivery , 2023 Sitc Annual Meeting , Phase 1 Perio 01 Trial ,